Recent Updates
Recently added Catalysts
WAT Positive Sentiment Score: 85/100

Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing Waters Corporation (NYSE: WAT) and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream...

Key Takeaway: Waters Corporation and Sartorius have expanded their collaboration to develop integrated analytical solutions for downstream biomanufacturing. This partnership enhances their previous agreement focused on upstream bioprocessing analytics. The collaboration aims to provide bioprocess engineers with real-time analytical data, improving yields and reducing waste during the drug production process. The integration of Waters' chromatography system with Sartorius' chromatography platform is expected to streamline quality checks, significantly impacting production efficiency.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to enhance downstream biomanufacturing analytics.
  • Integration of technologies is expected to optimize drug production costs.
  • Real-time analytics will streamline quality checks and reduce production time.
  • The partnership has potential benefits for increasing yields and reducing waste.

Full Press Release Details

MILFORD, Mass. and GOETTINGEN, Germany , June 5, 2023 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics. Software and hardware integrations between the Waters™ PATROL™ UltraPerformance Liquid Chromatography (UPLC™) Process
Analysis System and the Sartorius™ Resolute ® BioSMB™ multi-column chromatography platform will give bioprocess engineers access to more comprehensive analytical data for downstream batch and continuous manufacturing, improving yields while reducing waste and driving down biomanufacturing costs.
Waters Corporation and Sartorius Expand Their Collaboration into Downstream Bioprocessing Analytics
"Now that intensified, continuous manufacturing of biologics is becoming a reality, there is a greater need for real-time analytical measurement," said René Fáber, Head of Bioprocess Solutions Division, Sartorius. "The value of combining technologies from Sartorius and Waters lies in bringing fundamentally important analytics to the point where it is needed and giving bioprocess engineers a more complete understanding of their downstream manufacturing processing and its effects on drug product quality. We believe this can have significant impacts on drug production costs by helping to increase yields and reduce waste."
In-process sampling and the analysis of biological drugs sent to a central laboratory can take weeks before the results of necessary quality checks are in. Waters and Sartorius have shown how bioprocess scientists can streamline these analytics, so that product quality tests for protein A, aggregation and charge variants occur closer to the process, potentially saving weeks of production time. This has a positive impact on total process yield and product quality because the individual downstream unit operation can be further optimized much more easily, and corrective actions can be taken much faster.
Additional Resources
About Sartorius ( www.Sartorius.com )
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly, and economically. The company based in Goettingen, Germany , has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros . At the end of 2022, around 16,000 employees were working for customers around the globe.
About Waters Corporation ( www.waters.com )
Waters Corporation (NYSE: WAT ), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,200 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters Contact:
Brian J. Murphy PR Manager, Corporate Communications Waters Corporation [email protected] +1 508-482-2614
Sartorius Contact:
Tim Meyer Manager of Content Operations Sartorius [email protected] +1 608-540-8269
_____________________________
i Evolving Analytics in the Upstream Lab by Using the Power of LC-MS , a Waters/Sartorius webinar
SOURCE Waters Corporation

21 %

Frequently Asked Questions

What is the goal of the Waters and Sartorius collaboration?

The collaboration aims to develop analytical solutions for downstream biomanufacturing.

How will the partnership benefit bioprocess engineers?

It provides access to comprehensive analytical data, enhancing yields and reducing waste.

What challenge does this collaboration address in biomanufacturing?

It addresses the need for real-time analytical measurements in drug manufacturing.

How does this collaboration streamline product quality testing?

It allows for in-process sampling, shortening the time for quality test results.

What impact does faster testing have on drug production?

Faster testing improves process yield and allows for quicker corrective actions.

Last updated: Jun 5, 2023